Prevention of postmenopausal bone loss by tiludronate.
76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 months, half the patients received tiludronate 100 mg daily, while the others received placebo. During the second 6 months, all patients received placebo. Bone mineral density of the lumbar spine decreased significantly by 2.1% (SE 0.8%) in the placebo group and did not significantly change in the tiludronate group (+1.33 [0.8]%). The difference in response between the groups was significant, as were the differences between values for corrected urinary hydroxyproline and calcium. Treatment with tiludronate was not followed by increased secretion of parathyroid hormone. A 6 month course of oral tiludronate may counteract postmenopausal bone loss for at least a year by decreasing bone resorption.
Reginster
J Y
JY
Bone Metabolism Unit, University of Liege, Belgium.
Lecart
M P
MP
Deroisy
R
R
Sarlet
N
N
Denis
D
D
Ethgen
D
D
Collette
J
J
Franchimont
P
P
D015502:Absorptiometry, Photon; D000284:Administration, Oral; D015519:Bone Density; D001862:Bone Resorption / Q000517:prevention & control / Q000652:urine; D002118:Calcium / Q000652:urine; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008159:Lumbar Vertebrae / Q000032:analysis; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control* / Q000652:urine; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D004164:Diphosphonates; C058651:tiludronic acid; D006909:Hydroxyproline; D002118:Calcium